LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.
Jean-Pascal Machiels, Jérôme Fayette, Robert Haddad...
https://pubmed.ncbi.nlm.nih.gov/40511820/Active, Not Recruiting
Led by Genmab · Updated on 2026-11-02
699
Participants Needed
202
Research Sites
130 weeks
Total Duration
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
CONDITIONS
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Genmab
Lead Sponsor
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria may apply.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Jean-Pascal Machiels, Jérôme Fayette, Robert Haddad...
https://pubmed.ncbi.nlm.nih.gov/40511820/Genmab
Lead Sponsor